Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1
- 1 February 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (2) , 200-214
Abstract
Checkpoint blockade therapies targeting PD-1/PD-L1 and CTLA-4 are clinically successful but also evoke adverse events due to systemic T-cell activation. We engineered a bispecific, mAb targeting CD28 homolog (CD28H), a newly identified B7 family receptor that is constitutively expressed on T and natural killer (NK) cells, with a PD-L1 antibody to potentiate tumor-specific immune responses. The bispecific antibody led to T-cell costimulation, induced NK-cell cytotoxicity of PD-L1–expressing tumor cells, and activated tissue-resident memory CD8+ T cells. Mechanistically, the CD28H agonistic arm of the bispecific antibody reduced PD-L1/PD-1–induced SHP2 phosphorylation while simultaneously augmenting T-cell receptor signaling by activating the MAPK and AKT pathways. This bispecific approach could be used to target multiple immune cells, including CD8+ T cells, tissue-resident memory T cells, and NK cells, in a tumor-specific manner that may lead to induction of durable, therapeutic antitumor responses.Keywords
All Related Versions
Funding Information
- AstraZeneca
This publication has 42 references indexed in Scilit:
- B7-H5 costimulates human T cells via CD28HNature Communications, 2013
- Targeting T cells to tumor cells using bispecific antibodiesCurrent Opinion in Chemical Biology, 2013
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2Journal of Experimental Medicine, 2012
- Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesisMolecular Biology of the Cell, 2012
- The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and MetabolismImmunity, 2010
- The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease MediatorsJournal of Molecular Biology, 2009
- Bispecific T-Cell Engaging Antibodies for Cancer TherapyCancer Research, 2009
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display librariesGene, 1997
- A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibodyMolecular Immunology, 1993